^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
KSQ-004EX
i
Other names: KSQ-004EX, KSQ-004
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
KSQ Therap
Drug class:
Immunostimulant
Related drugs:
2ms
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=141, Not yet recruiting, M.D. Anderson Cancer Center
New P1/2 trial • Metastases
|
cyclophosphamide • fludarabine IV • KSQ-004EX
3years
KSQ-004: Unbiased pair-wise discovery of SOCS1 and Regnase-1 as the top CRISPR/Cas9 dual-edit combination enhancing in vivo TIL potency against solid tumors (SITC 2021)
Conclusions We used a novel CRISPR^2 screen approach to identify Regnase-1/SOCS1 as the top dual edit combination enhancing T cell function in the tumor microenvironment. We translated these findings to therapeutic use with the discovery of KSQ-004, a dual-edited eTIL therapy engineered that possesses enhanced anti-tumor potency and persistence against solid tumors.
Preclinical
|
IFNG (Interferon, gamma) • SOCS1 (Suppressor Of Cytokine Signaling 1)
|
KSQ-004EX
Share via
